CSL AGM In Melbourne In Focus As Healthcare Giant Provides Investor Checkpoint

MARKET OVERVIEW
ASX 200 closed slightly higher at 8837.40 on 27 October 2026, up 27.5 points or 0.31 percent after low of 8773.40. Financials main drag, materials bounced. CSL traded at $123.06 with 7.74 percent return over last 7 days, but year to date down 28.44 percent. Healthcare weight on ASX around 9 percent, CSL alone around 5.5 percent of index, so moves impact broader market.

Consumer confidence ANZ-Roy Morgan at 67.9 fourth week below 70, down 17.9 points year on year. Inflation expectations 6.3 percent. ANZ expects trimmed mean 1.0 percent for quarter potentially pushing RBA to 4.85 percent in November. ASX 200 futures flat down 6 points after Wall Street rallied on AI optimism.

CSL BEHRING - PLASMA BUSINESS OBSERVATIONS
CSL Behring is core contributor with approximately $11.2b annual sales from immunoglobulins and albumin.

Key operational metrics for educational understanding:

1. Plasma Collection: 10.5 million litres annually, around 300 collection centers in US, cost per litre around $165 currently, target $150 by 2027 through Rika plasmapheresis device. Rika saves 10 minutes per donation and $5 per litre. Donor fee around $60 per donation in US.
2. Yield and Cost: Immunoglobulin yield per litre and albumin extraction drive gross margin. Gross margin for Behring around 48 to 52 percent, with collection cost being largest variable. Freight and testing add $12 per litre.
3. Demand: IG demand growing 8 to 10 percent annually globally, driven by immunodeficiency and neurology use. US accounts for 40 percent of global IG demand, Europe 30 percent.

SEQIRUS - FLU VACCINE BUSINESS
Seqirus contributes around $2.1b sales, 34 percent market share in US flu vaccines, 20 percent in UK. Cell-based FLUCELVAX and adjuvanted FLUAD drive differentiation. Flu vaccine pricing $22 to $28 per dose in US, $15 in UK. Manufacturing at Holly Springs and Liverpool. Seasonal demand Q2-Q3 in Northern Hemisphere.

VIFOR - IRON DEFICIENCY
Vifor contributes around $800m sales with 62 percent gross margin. Ferinject / Injectafer for iron deficiency in CKD and heart failure. Market share 35 percent in IV iron. Pricing $400 to $600 per treatment course.

R&D PIPELINE
R&D spend around $1.3b annually, 11 percent of sales. Key programs:

• ANDEMBRY (garadacimab) for Hereditary Angioedema: Phase 3 showed 85 percent attack rate reduction, monthly dosing versus twice monthly competitors. Peak sales estimate $500m to $800m.
• CSL112 (Apolipoprotein A-I) for acute coronary syndrome: Phase 3 AEGIS-II readout focus.
• Gene therapy for Hemophilia B - HEMGENIX one-time therapy priced $3.5m in US, royalties to CSL.

BALANCE SHEET CONTEXT
Net debt around $10b after Vifor acquisition $11.7b in 2022. Leverage 2.1x EBITDA. Interest cost 4.5 percent average. Free cash flow $2.2b. Dividend payout 40 to 50 percent. Capex $1.2b including new Marburg facility $500m and Broadmeadows expansion.

MACRO AND SECTOR ROTATION
Defensive sectors such as healthcare, consumer staples and telecommunications can outperform during risk-off periods. On 27 Oct materials and energy outperformed when China eased. PBOC injected record 1.01 trillion yuan, 5-year yield hit record low 1.34 percent, supporting industrial demand. BHP up 2.3 percent to $56.93, Rio up 1.6 percent to $148.92, South32 up 1.8 percent.

For CSL, AUD USD impacts earnings as 80 percent of sales in USD/EUR/CHF and 60 percent costs in USD. AUD stronger helps costs but hurts translation. Universal Store DTC sales up 9.3 percent shows consumer discretionary can still perform in select brands.

WHAT TO WATCH NEXT

• Behring gross margin recovery path from $165 to $150 per litre target by FY27.
• Seqirus flu season uptake in US and UK winter 2026.
• RBA decision 4 Nov and CPI 28 Oct - impact on AUD and discount rates for long duration healthcare stocks.